• Please log in or register to access this feature.
You have free access to this content

Chapter 2: Diagnosis and surveillance

Article first published online: 19 MAY 2010

DOI: 10.1111/j.1872-034X.2010.00655.x

Issue

Hepatology Research

Hepatology Research

Special Issue: Clinical Practice Guidelines for Hepatocellular Carcinoma - The Japan Society of Hepatology 2009 update

Volume 40, Issue Supplement s1, pages 16–47, June 2010

Additional Information

How to Cite

(2010), Chapter 2: Diagnosis and surveillance. Hepatology Research, 40: 16–47. doi: 10.1111/j.1872-034X.2010.00655.x

Publication History

  1. Issue published online: 19 MAY 2010
  2. Article first published online: 19 MAY 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (203K)

REFERENCES

  • 1
    LF07209 Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2 (8256): 1129–33.
  • 2
    LF07205 Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991; 51: 5621–5.
  • 3
    LF03825 Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–801.
  • 4
    LF07208 Lu SN, Lin TM, Chen CJ et al. A case–control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988; 62 (9): 2051–5.
    Direct Link:
  • 5
    LF07206 Chen CJ, Liang KY, Chang AS et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 1991; 13: 398–406.
    Direct Link:
  • 6
    LF03877 Lin TM, Chen CJ, Lu SN et al. Hepatitis B virus e antigen and primary hepatocellular carcinoma. Anticancer Res 1991; 11 (6): 2063–5.
  • 7
    LF07198 Tsai JF, Jeng JE, Ho MS et al. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996; 73: 1498–502.
  • 8
    LF07199 Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21: 77–82.
  • 9
    LF07202 Liang TJ, Jeffers LJ, Reddy KR et al. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993; 18 (6): 1326–33.
  • 10
    LF03575 Tradati F, Colombo M, Mannucci PM et al. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C The Study Group of the Association of Italian Hemophilia Centers. Blood 1998; 91: 1173–7.
  • 11
    LF02404 Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112 (2): 463–72.
  • 12
    LF03633 Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26 (5): 1138–42.
    Direct Link:
  • 13
    LF07167 Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001; 96 (4): 1160–3.
  • 14
    LF07207 Mayans MV, Calvet X, Bruix J et al. Risk factors for hepatocellular carcinoma in Catalonia, Spain. Int J Cancer 1990; 46: 378–81.
    Direct Link:
  • 15
    LF07204 Tanaka K, Hirohata T, Takeshita S et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case–control study in Fukuoka, Japan. Int J Cancer 1992; 51: 509–14.
    Direct Link:
  • 16
    LF07203 Mohamed AE, Kew MC, Groeneveld HT. Alcohol consumption as a risk factor for hepatocellular carcinoma in urban southern African blacks. Int J Cancer 1992; 51: 537–41.
    Direct Link:
  • 17
    LF07193 Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323–31.
  • 18
    LF07194 Chiesa R, Donato F, Tagger A et al. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 2000; 9: 213–16.
  • 19
    LF07182 Yu Mctong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991; 83: 1820–6.
  • 20
    LF07195 Kuper H, Tzonou A, Kaklamani E et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85: 498–502.
    Direct Link:
  • 21
    LF12093 Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30 A: 344–50.
  • 22
    LF12094 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–38.
  • 23
    LF12096 Muto Y, Sato S, Watanabe A et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006; 35: 204–14.
  • 24
    LF12097 Adami HO, Chow WH, Nyren O et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472–7.
  • 25
    LF12098 Wideroff L, Gridley G, Mellemkjaer L et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360–5.
  • 26
    LF12099 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126 (2): 460–8.
  • 27
    LF12100 Matsuo M. Association between diabetes mellitus and hepatocellular carcinoma: results of a hospital- and community-based case-control study. Kurume Med J 2003; 50 (3–4): 91–8.
  • 28
    LF12101 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36 (6): 1349–54.
  • 29
    LF12102 Hashimoto E, Yatsuji S, Kaneda H et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2005; 33 (2): 72–6.

REFERENCES

REFERENCES

  • 1
    LF01982 Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251–9.
  • 2
    LF02687 Cottone M, Turri M, Caltagirone M et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994; 21: 1029–34.
  • 3
    LF02689 Pateron D, Ganne N, Trinchet JCC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65–71.
  • 4
    LF03727 Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22 (2): 432–8.
  • 5
    LF03069 Maringhini A, Cottone M, Sciarrino E et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci 1988; 33: 47–51.
  • 6
    LJ03471 Saito S, Ikeda K, Koida I. Diagnostic ability and limitations of abdominalultrasound and CT for surveillance of hepatocellular carcinoma. Shokaki-ka 1992; 17(6): 505–10 (in Japanese).
  • 7
    LF06198 Libbrecht L, Bielen D, Verslype C et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8: 749–61.
    Direct Link:
  • 8
    LF02001 Rode A, Bancel B, Douek P et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001; 25: 327–36.
  • 9
    LF00807 Miller WJ, Federle MP, Campbell WL. Diagnosis and staging of hepatocellular carcinoma: comparison of CT and sonography in 36 liver transplantation patients. AJR Am J Roentgenol 1991; 157: 303–6.
  • 10
    LF01867 Bennett GL, Krinsky GA, Abitbol RJ, Kim SY, Theise ND, Teperman LW. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR Am J Roentgenol 2002; 179: 75–80.
  • 11
    LF00406 Achkar JP, Araya V, Baron RL, Marsh JW, Dvorchik I, Rakela J. Undetected hepatocellular carcinoma: clinical features and outcome after liver transplantation. Liver Transpl Surg 1998; 4: 477–82.
    Direct Link:
  • 12
    LF02231 Horigome H, Nomura T, Saso K, Itoh M, Joh T, Ohara H. Limitations of imaging diagnosis for small hepatocellular carcinoma: comparison with histological findings. J Gastroenterol Hepatol 1999; 14: 559–65.
    Direct Link:
  • 13
    LF02462 Solmi L, Primerano AM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol 1996; 91: 1189–94.
  • 14
    LF02114 Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330–5.
    Direct Link:
  • 15
    LF03822 Tang ZY, Yu YQ, Zhou XD, Yang BH, Ma ZC, Lin ZY. Subclinical hepatocellular carcinoma: an analysis of 391 patients. J Surg Oncol Suppl 1993; 3: 55–8.
    Direct Link:
  • 16
    LF02945 Oka H, Kurioka N, Kim K et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12 (4 Pt 1): 680–7.
    Direct Link:
  • 17
    LF01871 Caturelli E, Bartolucci F, Biasini E et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 397–405.
    Direct Link:
  • 18
    LF03905 Colombo M, De Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675–80.

REFERENCES

  • 1
    LF02949 Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990; 11: 481–7.
    Direct Link:
  • 2
    LF03381 Ikoma J, Kaito M, Ishihara T et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002; 49 (43): 235–8.
  • 3
    LF03437 Oka H, Saito A, Ito K et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001; 16: 1378–83.
    Direct Link:
  • 4
    LF03505 Shimauchi Y, Tanaka M, Kuromatsu R et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000; 7: 249–56.
  • 5
    LF03518 Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94 (3): 650–4.
    Direct Link:
  • 6
    LF03576 Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82: 1643–8.
    Direct Link:
  • 7
    LF03656 Nomura F, Ishijima M, Horikoshi A, Nakai T, Ohnishi K. Determination of serum desgamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996; 91: 1380–3.
  • 8
    LF03726 Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995; 22 (3): 802–7.
    Direct Link:
  • 9
    LF03754 Saitoh S, Ikeda K, Koida I et al. Serum des-gamma-carboxyprothrombin concentration determined by the avidin-biotin complex method in small hepatocellular carcinomas. Cancer 1994; 74 (11): 2918–23.
    Direct Link:
  • 10
    LF03757 Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994; 73 (10): 2464–71.
    Direct Link:
  • 11
    LF03801 Taketa K, Endo Y, Sekiya C et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993; 53 (22): 5419–23.
  • 12
    LF03804 Kasahara A, Hayashi N, Fusamoto H et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993; 38: 2170–6.
  • 13
    LF04001 Tanabe Y, Ohnishi K, Nomura F, Iida S. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma. Am J Gastroenterol 1988; 83: 1386–9.
  • 14
    LF04008 Fujiyama S, Morishita T, Hashiguchi O, Sato T. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988; 61: 1621–8.
    Direct Link:
  • 15
    LF11056 Wang CS, Lin CL, Lee HC et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005; 11: 6115–19.

REFERENCES

  • 1
    LF02852 Kishi K, Sonomura T, Mitsuzane K et al. Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis. Radiat Med 1992; 10 (5): 189–95.
  • 2
    LF03862 Hsieh MY, Lu SN, Wang LY et al. Alpha-fetoprotein in patients with hepatocellular carcinoma after transcatheter arterial embolization. J Gastroenterol Hepatol 1992; 7: 614–17.
    Direct Link:

REFERENCES

  • 1
    LF10092 Colli A, Fraquelli M, Casazza G et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513–23.
    Direct Link:
  • 2
    LF00606 Taourel PG, Pageaux GP, Coste V et al. Small hepatocellular carcinoma in patients undergoing liver transplantation: detection with CT after injection of iodized oil. Radiology 1995; 197: 377–80.
  • 3
    LF01932 Kubota K, Hisa N, Nishikawa T et al. Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging 2001; 26: 184–90.
  • 4
    LF01895 Stoker J, Romijn MG, De Man RA et al. Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma. Gut 2002; 51: 105–7.
  • 5
    LF10938 Kang BK, Lim JH, Kim SH et al. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology 2003; 226: 79–85.
  • 6
    LF10045 Kim SH, Choi D, Kim SH et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2005; 184 (4): 1069–76.
  • 7
    LF10956 Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 2006; 238 (2): 531–41.
  • 8
    LF02182 Tang Y, Yamashita Y, Arakawa A et al. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxidesenhanced MR imaging. AJR Am J Roentgenol 1999; 172 (6): 1547–54.
  • 9
    LF05734 Matsuo M, Kanematsu M, Itoh K et al. Detection of malignant hepatic tumors: comparison of gadolinium- and ferumoxide-enhanced MR imaging. AJR Am J Roentgenol 2001; 177 (3): 637–43.
  • 10
    LF10423 Kwak HS, Lee JM, Kim CS. Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol 2004; 14: 447–57.
  • 11
    LF05711 Kawata S, Murakami T, Kim T et al. Multidetector CT: diagnostic impact of slice thickness on detection of hypervascular hepatocellular carcinoma. AJR Am J Roentgenol 2002; 179: 61–6.

REFERENCES

  • 1
    LF12103 Krinsky GA, Nguyen MT, Lee VS et al. Dysplastic nodules and hepatocellular carcinoma: sensitivity of digital subtraction hepatic arteriography with whole liver explant correlation. J Comput Assist Tomogr 2000; 24: 628–34.
  • 2
    LF00474 Spreafico C, Marchiano A, Mazzaferro V et al. Hepatocellular carcinoma in patients who undergo liver transplantation: sensitivity of CT with iodized oil. Radiology 1997; 203 (2): 457–60.
  • 3
    LF10030 Steingruber IE, Mallouhi A, Czermak BV et al. Pretransplantation evaluation of the cirrhotic liver with explantation correlation: accuracy of CT arterioportography and digital subtraction hepatic angiography in revealing hepatocellular carcinoma. AJR Am J Roentgenol 2003; 181: 99–108.
  • 4
    LF05879 Bizollon T, Rode A, Bancel B et al. Diagnostic value and tolerance of Lipiodol-computed tomography for the detection of small hepatocellular carcinoma: correlation with pathologic examination of explanted livers. J Hepatol 1998; 28: 491–6.
  • 5
    LF10371 Bhattacharjya S, Bhattacharjya T, Quaglia A et al. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of preoperative imaging, explant histology and prognostic histologic indicators. Dig Surg 2004; 21: 152–9.
  • 6
    LF02001 Rode A, Bancel B, Douek P et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001; 25: 327–36.
  • 7
    LF10546 Burrel M, Llovet JM, Ayuso C et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38 (4): 1034–42.
  • 8
    LF10023 Noguchi Y, Murakami T, Kim T et al. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol 2003; 180 (2): 455–60.
  • 9
    LF05773 Lim JH, Kim CK, Lee WJ et al. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol 2000; 175 (3): 693–8.
  • 10
    LF10051 Kim YK, Kim CS, Chung GH et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol 2006; 186: 149–57.
  • 11
    LF06200 Krinsky GA, Lee VS, Theise ND et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001; 219 (2): 445–54.
  • 12
    LF10045 Kim SH, Choi D, Kim SH et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2005; 184 (4): 1069–76.
  • 13
    LF10423 Kwak HS, Lee JM, Kim CS. Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol 2004; 14: 447–57.
  • 14
    LF05752 Choi D, Kim SH, Lim JH et al. Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr 2001; 25: 777–85.
  • 15
    LF12141 Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5): 1208–36.
    Direct Link:
  • 16
    LF12138 Takayasu K, Furukawa H, Wakao F et al. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR Am J Roentgenol 1995; 164 (4): 885–90.
  • 17
    LF12145 Winter TC, 3rd, Takayasu K, Muramatsu Y et al. Early advanced hepatocellular carcinoma: evaluation of CT and MR appearance with pathologic correlation. Radiology 1994; 192: 379–87.
  • 18
    LF12140 International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22 (3): 983–93.
  • 19
    LF12139 Ferrell LD, Crawford JM, Dhillon AP, Scheuer PJ, Nakanuma Y. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993; 17: 1113–23.

REFERENCES

  • 1
    LF06209 Matsui O, Kadoya M, Kameyama T et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991; 178 (2): 493–7.
  • 2
    LJ03368 Tochio H, Tomita S, Kudo M et al. Growth rate of hepatocellular carcinomaandarterial vascularity detected by US angiography. Acute Hapatol Jap 1992; 33(10): 758–65 (in Japanese).
  • 3
    LF06204 Hayashi M, Matsui O, Ueda K et al. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol 1999; 172 (4): 969–76.
  • 4
    LF05724 Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002; 225: 143–9.
  • 5
    LF02538 Ueda K, Kitagawa K, Kadoya M, Matsui O, Takashima T, Yamahana T. Detection of hypervascular hepatocellular carcinoma by using spiral volumetric CT: comparison of US and MR imaging. Abdom Imaging 1995; 20: 547–53.
  • 6
    LF05710 Lim JH, Choi D, Kim SH et al. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol 2002; 179: 67–73.
  • 7
    LF05839 Fujita T, Ito K, Honjo K, Okazaki H, Matsumoto T, Matsunaga N. Detection of hepatocellular carcinoma: comparison of T2-weighted breath-hold fast spin-echo sequences and high-resolution dynamic MR imaging with a phased-array body coil. J Magn Reson Imaging 1999; 9: 274–9.
    Direct Link:
  • 8
    LF02001 Rode A, Bancel B, Douek P et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001; 25: 327–36.
  • 9
    LF12082 Awai K, Hiraishi K, Hori S. Effect of contrast material injection duration and rate on aortic peak time and peak enhancement at dynamic CT involving injection protocol with dose tailored to patient weight. Radiology 2004; 230: 142–50.
  • 10
    LF06202 Imai Y, Murakami T, Yoshida S et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000; 32: 205–12.
    Direct Link:
  • 11
    LF02182 Tang Y, Yamashita Y, Arakawa A et al. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging. AJR Am J Roentgenol 1999; 172 (6): 1547–54.
  • 12
    LF05734 Matsuo M, Kanematsu M, Itoh K et al. Detection of malignant hepatic tumors: comparison of gadolinium- and ferumoxide-enhanced MR imaging. AJR Am J Roentgenol 2001; 177 (3): 637–43.

REFERENCES

  • 1
    LJ05444 Kudo M, Ibuki Y, Fujimi K. Kanzousaibou no shindan ni kan scintigram wa hitsuyou ka? Rinshouhousyasen 1987; 32: 901–8.
  • 2
    LF03472 Iwata Y, Shiomi S, Sasaki N et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 2000; 14: 121–6.
  • 3
    LF06001 Torizuka T, Tamaki N, Inokuma T et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811–17.
  • 4
    LF10939 Teefey SA, Hildeboldt CC, Dehdashti F et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226 (2): 533–42.
  • 5
    LF00673 Torizuka T, Tamaki N, Inokuma T et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35: 1965–9.
  • 6
    LF10765 Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48: 902–9.

REFERENCES

REFERENCES

  • 1
    LJ06226 Committee for Ultrasonic Diagnosis Criteria at the Japan Society of Ultrasonics in Medicine. [Guidelines for ultrasonic diagnosis of liver tumors (1988-11-30)]. Japanese Journal of Medical Ultrasonics 1989; 16: 108–11. (in Japanese.)
  • 2
    LF03120 Yoshida T, Matsue H, Okazaki N, Yoshino M. Ultrasonographic differentiation of hepatocellular carcinoma from metastatic liver cancer. J Clin Ultrasound 1987; 15: 431–7.
    Direct Link:
  • 3
    LF02848 Nihei T, Ebara M, Ohto M, Kondo F. [Study of sonographic findings of small hepatocellular carcinoma based on its pathologic findings]. Nippon Shokakibyo Gakkai Zasshi 1992; 89 (6): 1360–8. (In Japanese.)
  • 4
    LF02784 Gibo Y, Desmet V. Study of the usefulness and the limits of ultrasonic diagnostic criteria for diagnosis of liver tumours. Acta Gastroenterol Belg 1992; 55 (5–6): 405–14.
  • 5
    LF03069 Maringhini A, Cottone M, Sciarrino E et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci 1988; 33: 47–51.
  • 6
    LF01935 Tanaka S, Ioka T, Oshikawa O, Hamada Y, Yoshioka F. Dynamic sonography of hepatictumors. AJR Am J Roentgenol 2001; 177: 799–805.
  • 7
    LF02058 Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Maekawa K. Hepatocellular carcinoma: depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual-display mode. Radiology 2001; 220: 349–56.
  • 8
    LF10901 Yamamoto K, Shiraki K, Nakanishi S et al. Usefulness of digital subtraction imaging with Levovist in the diagnosis of hepatocellular carcinomas. Oncol Rep 2005; 13: 95–9.
  • 9
    LF11068 Numata K, Isozaki T, Morimoto M et al. Prospective study of differential diagnosis of hepatic tumors by pattern-based classification of contrastenhanced sonography. World J Gastroenterol 2006; 12: 6290–8.
  • 10
    LF10317 Jung EM, Kubale R, Jungius KP, Jung W, Lenhart M, Clevert DA. Vascularization of liver tumors – preliminary results with Coded Harmonic Angio (CHA), phase inversion imaging, 3D power Doppler and contrast medium-enhanced B-flow with second generation contrast agent (Optison). Clin Hemorheol Microcirc 2006; 34: 483–97.
  • 11
    LF10593 Wen YL, Zhou P, Kudo M. Detection of intratumoral vascularity in small hepatocellular carcinoma by coded phase inversion harmonics. Intervirology 2004; 47 (3–5): 169–78.
  • 12
    LF10042 Giorgio A, Ferraioli G, Tarantino L et al. Contrastenhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol 2004; 183 (5): 1319–26.
  • 13
    LF10570 Strobel D, Raeker S, Martus P, Hahn EG, Becker D. Phase inversion harmonic imaging versus contrast-enhanced power Doppler sonography for the characterization of focal liver lesions. Int J Colorectal Dis 2003; 18: 63–72.
  • 14
    LF01908 Kitamura H, Kawasaki S, Nakajima K, Ota H. Correlation between microbubble contrastenhanced color doppler sonography and immunostaining for Kupffer cells in assessing the histopathologic grade of hepatocellular carcinoma: preliminary results. J Clin Ultrasound 2002; 30: 465–71.
    Direct Link:
  • 15
    LF01921 Dill-Macky MJ, Burns PN, Khalili K, Wilson SR. Focal hepatic masses: enhancement patterns with SH U 508 A and pulse-inversion US. Radiology 2002; 222: 95–102.
  • 16
    LF10782 Xu HX, Liu GJ, Lu MD et al. Characterization of small focal liver lesions using real-time contrast-enhanced sonography: diagnostic performance analysis in 200 patients. J Ultrasound Med 2006; 25: 349–61.
  • 17
    LF10945 Quaia E, Calliada F, Bertolotto M et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004; 232 (2): 420–30.
  • 18
    LF10777 Von Herbay A, Vogt C, Haussinger D. Pulse inversion sonography in the early phase of the sonographic contrast agent Levovist: differentiation between benign and malignant focal liver lesions. J Ultrasound Med 2002; 21: 1191–200.
  • 19
    LF10425 Nicolau C, Catala V, Vilana R et al. Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation. Eur Radiol 2004; 14: 1092–9.

REFERENCES

  • 1
    LF10062 Minami Y, Kudo M, Chung H et al. Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. AJR Am J Roentgenol 2007; 188 (2): 489–94.
  • 2
    LF12083 Kawasoe H, Eguchi Y, Mizuta T et al. Radiofrequency ablation with the real-time virtual sonography system for treating hepatocellular carcinoma difficult to detect by ultrasonography. J Clin Biochem Nutr 2007; 40: 66–72.

REFERENCES

  • 1
    LF10024 Minami Y, Kudo M, Kawasaki T et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003; 180 (3): 703–8.
  • 2
    LF10316 Jung EM, Kubale R, Jungius KP. Vascularization and perfusion of hepatocellular carcinoma: assessment with contrast-enhanced ultrasound using perflutren protein-type A microspheres. Clin Hemorheol Microcirc 2005; 33: 63–73.
  • 3
    LF10779 Youk JH, Lee JM, Kim CS. Therapeutic response evaluation of malignant hepatic masses treated by interventional procedures with contrast-enhanced agent detection imaging. J Ultrasound Med 2003; 22: 911–20.
  • 4
    LF10810 Kono Y, Lucidarme O, Choi SH et al. Contrastenhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18 (1 Pt 1): 57–65.
  • 5
    LF10029 Wen YL, Kudo M, Zheng RQ et al. Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003; 181: 57–63.
  • 6
    LF10653 Vilana R, Llovet JM, Bianchi L et al. Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound 2003; 31: 119–28.
    Direct Link:
  • 7
    LF10404 Kim CK, Choi D, Lim HK et al. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrastenhanced agent detection imaging. Eur J Radiol 2005; 56: 66–73.
  • 8
    LF10781 Choi D, Lim HK, Lee WJ et al. Early assessment of the therapeutic response to radio frequency ablation for hepatocellular carcinoma: utility of gray scale harmonic ultrasonography with a microbubble contrast agent. J Ultrasound Med 2003; 22: 1163–72.
  • 9
    LF10734 Gaiani S, Celli N, Piscaglia F et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004; 41: 421–6.
View Full Article (HTML) Get PDF (203K)